ERBB2 amplification is a driver oncogenic alteration in many cancers and it has recently
been incorporated among therapeutically actionable biomarkers also in metastatic …

Simple Summary Metastatic colorectal cancer is a complex, prevalent, and life-threatening
disease influenced by various factors that affect its progression, evolution, and treatment …

Abstract Background Since June 2019, cancer genomic profiling (CGP) tests have been
reimbursed by the National Health Insurance system in Japan, with restrictions for …

Simple Summary Colorectal cancer with a mutation in an oncogene BRAF has paid much
attention, as it comprises a population with dismal prognosis since two decades ago. A …

Abstract Lessons Learned A biweekly TAS‐102 plus BEV schedule in patients with heavily
pretreated mCRC showed equivalent efficacy with less toxicity compared with the current …

Colorectal cancer (CRC) is the third most common cancer diagnosed worldwide and is
heterogeneous both morphologically and molecularly. In an era of personalized medicine …

Computed tomography (CT), magnetic resonance imaging (MRI), and 18-fluorideoxyglucose
positron emission tomography (18FDG-PET) are historically the most accurate imaging …

Introduction Physicians must share decisions and choose personalised treatments
regarding patients´ beliefs and values. Objective To analyse the quality of the …

Opinion statement Colorectal cancer (CRC) is a major public health problem and the 2nd
leading-cause of cancer-related death worldwide. Around 30% of patients present with …

Abstract Anti-epidermal-growth-factor-receptor (EGFR) monoclonal antibodies (mAbs) are of
great significance for RAS and BRAF wild-type metastatic colorectal cancer (mCRC) …